• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Natus Medical beats the Street in Q4, announces business realignment

Natus Medical beats the Street in Q4, announces business realignment

February 25, 2022 By Danielle Kirsh

Natus MedicalNatus Medical (NSDQ:NTUS) this week posted fourth-quarter results that beat the overall consensus on Wall Street.

The Pleasanton, California-based company makes devices and software to diagnose, monitor and treat brain and nervous system disorders. It reported profits of $1.7 million, or 5¢ per share, on sales of $128.7 million for the three months ended Dec. 31, 2021, for a bottom-line loss of 66.5% on sales growth of 8.37% compared with Q4 2020.

Adjusted to exclude one-time items, earnings per share were 47¢, 3¢ ahead of The Street, where analysts were looking for sales of $125.8 million.

“I would like to thank our Natus teammates for their efforts to deliver growth in both revenue and income in the fourth quarter despite challenges from both COVID and supply chain-related constraints,” president and CEO Thomas Sullivan said in a news release. “Throughout the year we focused on ensuring our products were available to clinicians and despite incurring over $1.7 million in higher costs in the fourth quarter alone, our non-GAAP earnings per share increased more than 200%.”

Natus Medical said it is realigning its commercial organization to focus on clinical areas involving the brain, neural pathways and eight sensory nervous systems as part of its Q1 plans. It will transition to a matrix infrastructure of non-commercial resources to support innovation and growth for each clinical focus area. Because of this, Natus Medical is only providing annual guidance that excludes the impact of any acquisitions or divestitures.

Dr. Christopher Chung, Natus’ VP of quality and regulatory affairs and chief medical officer, plans to retire in April after 22 years at the company.

The company expects full-year 2022 revenue to be in the range of $491 million and $499 million with non-GAAP earnings per share between $1.36 and $1.49.

Shares in NTUS were up more than 15% at $27.64 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up 1%.

Filed Under: Diagnostics, Featured, MassDevice Earnings Roundup, News Well, Patient Monitoring, Wall Street Beat Tagged With: Natus Medical

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy